12.35
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$12.28
Aprire:
$12.28
Volume 24 ore:
377.34K
Relative Volume:
0.87
Capitalizzazione di mercato:
$349.86M
Reddito:
$157.75M
Utile/perdita netta:
$-29.73M
Rapporto P/E:
-10.65
EPS:
-1.16
Flusso di cassa netto:
$-21.00M
1 W Prestazione:
-0.72%
1M Prestazione:
+6.01%
6M Prestazione:
-16.67%
1 anno Prestazione:
-52.43%
Arcturus Therapeutics Holdings Inc Stock (ARCT) Company Profile
Nome
Arcturus Therapeutics Holdings Inc
Settore
Industria
Telefono
(858) 900-2660
Indirizzo
10628 SCIENCE CENTER DRIVE, SAN DIEGO, CA
Confronta ARCT con altri titoli
Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
---|---|---|---|---|---|---|
![]()
ARCT
Arcturus Therapeutics Holdings Inc
|
12.35 | 349.86M | 157.75M | -29.73M | -21.00M | -1.16 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
448.40 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
513.58 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
312.32 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
537.92 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
252.78 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Arcturus Therapeutics Holdings Inc Stock (ARCT) Upgrades & Downgrades
Data | Azione | Analista | Modifica della valutazione |
---|---|---|---|
2025-05-28 | Iniziato | Scotiabank | Sector Outperform |
2025-01-28 | Iniziato | BTIG Research | Buy |
2024-08-12 | Iniziato | Leerink Partners | Outperform |
2023-12-13 | Iniziato | Canaccord Genuity | Buy |
2023-07-24 | Iniziato | William Blair | Outperform |
2023-05-11 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
2022-11-14 | Ripresa | Wells Fargo | Overweight |
2022-11-10 | Downgrade | Robert W. Baird | Neutral → Underperform |
2022-11-03 | Aggiornamento | Citigroup | Neutral → Buy |
2022-11-02 | Aggiornamento | Barclays | Underweight → Equal Weight |
2022-08-10 | Downgrade | Raymond James | Mkt Perform → Underperform |
2022-07-19 | Ripresa | Cantor Fitzgerald | Overweight |
2022-05-11 | Aggiornamento | Robert W. Baird | Underperform → Neutral |
2022-04-21 | Downgrade | Citigroup | Buy → Neutral |
2022-01-31 | Aggiornamento | Raymond James | Underperform → Mkt Perform |
2021-08-12 | Downgrade | Raymond James | Mkt Perform → Underperform |
2021-08-11 | Downgrade | Goldman | Neutral → Sell |
2021-08-10 | Downgrade | Robert W. Baird | Neutral → Underperform |
2021-07-02 | Iniziato | Cantor Fitzgerald | Overweight |
2021-06-25 | Ripresa | Goldman | Neutral |
2021-06-21 | Downgrade | Barclays | Equal Weight → Underweight |
2021-06-04 | Ripresa | Robert W. Baird | Neutral |
2021-02-17 | Downgrade | B. Riley Securities | Neutral → Sell |
2021-01-19 | Downgrade | B. Riley Securities | Buy → Neutral |
2021-01-15 | Downgrade | B. Riley Securities | Buy → Neutral |
2021-01-07 | Iniziato | Wells Fargo | Overweight |
2020-12-29 | Downgrade | Barclays | Overweight → Equal Weight |
2020-12-29 | Downgrade | H.C. Wainwright | Buy → Neutral |
2020-12-29 | Downgrade | Raymond James | Outperform → Mkt Perform |
2020-12-29 | Downgrade | Robert W. Baird | Outperform → Neutral |
2020-12-23 | Downgrade | ROTH Capital | Buy → Sell |
2020-12-08 | Reiterato | B. Riley Securities | Buy |
2020-12-07 | Reiterato | B. Riley Securities | Buy |
2020-10-26 | Iniziato | Barclays | Overweight |
2020-10-06 | Iniziato | Citigroup | Buy |
2020-08-26 | Iniziato | Piper Sandler | Overweight |
2020-07-30 | Ripresa | ROTH Capital | Buy |
2020-07-16 | Iniziato | Raymond James | Outperform |
2020-07-13 | Iniziato | B. Riley FBR | Buy |
2020-06-09 | Downgrade | WBB Securities | Buy → Hold |
2020-02-11 | Iniziato | Robert W. Baird | Outperform |
2020-02-07 | Iniziato | Guggenheim | Buy |
2020-02-06 | Iniziato | Guggenheim | Buy |
2019-04-05 | Iniziato | H.C. Wainwright | Buy |
2018-09-20 | Aggiornamento | WBB Securities | Buy → Strong Buy |
2018-01-22 | Iniziato | Chardan Capital Markets | Buy |
Mostra tutto
Arcturus Therapeutics Holdings Inc Borsa (ARCT) Ultime notizie
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Shares Sold by Bank of America Corp DE - Defense World
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Shares Sold by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC - Defense World
Analysts Offer Predictions for ARCT FY2026 Earnings - Defense World
Two Sigma Investments LP Increases Stock Holdings in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) - Defense World
(ARCT) Pivots Trading Plans and Risk Controls - news.stocktradersdaily.com
Squarepoint Ops LLC Sells 22,752 Shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) - Defense World
Arcturus Therapeutics Holdings Inc (ARCT) Is A Good Stock To Invest In - Stocksregister
Arcturus Therapeutics Approves Key Proposals at Annual Meeting - TipRanks
Transcript : Arcturus Therapeutics Holdings Inc.Shareholder/Analyst Call - marketscreener.com
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Position Increased by Ameriprise Financial Inc. - Defense World
Nuveen Asset Management LLC Sells 10,221 Shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) - Defense World
BNP Paribas Financial Markets Sells 13,093 Shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) - Defense World
Wall Street Analysts Think Arcturus Therapeutics (ARCT) Could Surge 371.35%: Read This Before Placing a Bet - sharewise
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Shares Purchased by Deutsche Bank AG - Defense World
Arcturus Therapeutics to Attend Upcoming Investor Conferences - Business Wire
Arcturus Therapeutics (NASDAQ:ARCT) Now Covered by Analysts at Scotiabank - Defense World
Scotiabank Initiates Coverage of Arcturus Therapeutics Holdings (ARCT) with Sector Outperform Recommendation - Nasdaq
When the Price of (ARCT) Talks, People Listen - news.stocktradersdaily.com
Scotiabank Initiates Coverage on Arcturus Therapeutics (ARCT) | - GuruFocus
Arcturus Therapeutics (ARCT) Receives Positive Outlook with Potential Upside | ARCT Stock News - GuruFocus
Scotiabank Initiates Arcturus Therapeutics at Outperform - marketscreener.com
Man Group plc Sells 4,168 Shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) - Defense World
Arcturus Therapeutics’ SWOT analysis: mRNA innovator’s stock faces pivotal year - Investing.com India
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Given Average Recommendation of “Buy” by Brokerages - Defense World
Wall Street Zen Upgrades Arcturus Therapeutics (NASDAQ:ARCT) to “Hold” - Defense World
Arcturus Therapeutics Holdings (ARCT) Stock Analysis: A 481% Upside Potential Amidst Biotech Innovations - DirectorsTalk Interviews
Northern Trust Corp Has $4.35 Million Stock Position in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) - Defense World
Trend Tracker for (ARCT) - news.stocktradersdaily.com
Wells Fargo & Company Cuts Arcturus Therapeutics (NASDAQ:ARCT) Price Target to $45.00 - Defense World
Arcturus signals extended cash runway into 2028 with strategic shift toward CF and OTC mRNA therapeutics - MSN
FY2025 EPS Estimates for ARCT Raised by Cantor Fitzgerald - The AM Reporter
Leerink Partnrs Analysts Raise Earnings Estimates for ARCT - Defense World
Price T Rowe Associates Inc. MD Increases Stock Position in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) - Defense World
William Blair Brokers Boost Earnings Estimates for ARCT - Defense World
Wall Street Analysts Believe Arcturus Therapeutics (ARCT) Could Rally 503.6%: Here's is How to Trade - Yahoo Finance
Canaccord Genuity Group Issues Pessimistic Forecast for Arcturus Therapeutics (NASDAQ:ARCT) Stock Price - Defense World
Arcturus Therapeutics (ARCT): Wells Fargo Maintains Rating, Lowe - GuruFocus
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Q1 2025 Earnings Call Transcript - Insider Monkey
Wells Fargo Adjusts Price Target for Arcturus Therapeutics (ARCT) | ARCT Stock News - GuruFocus
Arcturus Therapeutics (ARCT) Set for Potential Upside with Citi's Confidence | ARCT Stock News - GuruFocus
Arcturus Therapeutics Holdings Inc earnings missed by $4.11, revenue fell short of estimates - Investing.com Nigeria
Canaccord Genuity Maintains Buy Rating on Arcturus Therapeutics (ARCT) | ARCT Stock News - GuruFocus
Demystifying Arcturus Therapeutics: Insights From 7 Analyst Reviews - Benzinga
Arcturus Therapeutics (ARCT) Price Target Revised by Canaccord | - GuruFocus
Arcturus Therapeutics Holdings Inc (ARCT) Q1 2025 Earnings: EPS - GuruFocus
Arcturus Therapeutics Holdings Inc (ARCT) Q1 2025 Earnings Call Highlights: Strategic Focus and ... - Yahoo Finance
Arcturus Therapeutics stock jumps 7% despite Q1 loss By Investing.com - Investing.com India
Arcturus Therapeutics Holdings Inc (ARCT) Q1 2025 Earnings Call - GuruFocus
Arcturus Therapeutics Reports Q1 2025 Financial Update - TipRanks
Arcturus Therapeutics (ARCT) Sees Strong Progress with Pipeline Programs - GuruFocus
Earnings call transcript: Arcturus Therapeutics Q1 2025 sees revenue drop, stock rises - Investing.com
Arcturus Therapeutics Holdings Inc Azioni (ARCT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):